Reduced-intensity conditioning transplantation (RICT) for chronic myeloid leukemia (CML).
| Ref. . | No. . | Protocol . | Disease . | Donor . | Median Age . | Response . | Median Follow-up (mos) . | NRM . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: NRM, non-relapse mortality; DFS, disease-free survival; OS, overall survival; Fd, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; Cy, cyclophosphamide; CP, chronic phase; VUD, Volunteer unrelated donor; BC, blast crisis; TBI, total body irradiation; DLI, donor lymphocyte infusions | ||||||||||
| 14 | 44 | Fd/Bu ± ATG 11 AP | 26 CP 15 VUD 7 BC | 19 Sib | 52 | Cyto remission = 26/31 Mol remission = 19/31 | 14.8 | 15/44 | 41% at 18 mos | 24/44 |
| 15 | 17 | Fd/Bu/ATG Fd/Bu/TBI | 16 CP1 1 AP | 17 Sib | 35 | Mol remission = 5 | 30 | 8/17 | 5/17 | 6/17 |
| 16 | 24 | Fd/Bu/ATG | 24 CP1 5 VUD | 18 Sib 1 father | 35 | Mol remission = 100% (3 required DLI) | 42 | Day 100 = 0% 3 deaths | 85% at 5 yrs | 85% at 5 yrs |
| 17 | 12 | Fd + Cyclo (120 mg/kg) | 8 CP1 5 CP2 | 12 Sib | 43 | Cyto remission = 5 (6 mos) Mol remission = 4 (1 yr) 8 mol remission with additional therapy | 12 | Day 100 = 0% | 4 deaths from relapse | 8/12 |
| 18 | 15 | Fd/Bu/ATG | All CP1 | 10 Sib, 5 VUD | 51 | Mol remission = 11 | 20 | 2/15 | 9/15 | 13/15 |
| 19 | 35 | Cy 80–120 mg/kg/TBI (8 Gy) | 26 CP1 9 CP2/AP | 19 Sib, 16 VUD | 51 | Cyto remission = 100% Mol remission = 85% | 30 | Day 100 = 11% 1 year 28.5% | 49% at 5 yrs | 59% at 2 yrs |
| 20 | 186 | Various | 118 CP1 26 CP2 30 AP 12 BC | 113 Sib 20 Other related 52 VUD | 50 | Overall 86.9% | 35 | Day 100 = 3.8% 2 yr = 18.9% | 33% at 3 yrs CP 43% at 3 yrs | 54% at 3 yrs CP1 69% at 3 yrs |
| 21 | 24 | 2 Gy TBI ± Fd | 14 CP1 4 CP2 6 AP | 24 Sib | 57.5 | Cyto remission = 15 Mol remission = 13 | 36 | CP1 15% > CP1 12% | Relapse at 2 yrs CP1 22% >CP1 64% | CP1 70% > CP1 56% |
| 22 | 24 | Bu/Cy/Fd | 24 CP | 24 Sib | 41 | Mol remission = 18/24 | 15 | 8% | 20/24 at 27 mos | 92% at 27 mos |
| Ref. . | No. . | Protocol . | Disease . | Donor . | Median Age . | Response . | Median Follow-up (mos) . | NRM . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: NRM, non-relapse mortality; DFS, disease-free survival; OS, overall survival; Fd, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; Cy, cyclophosphamide; CP, chronic phase; VUD, Volunteer unrelated donor; BC, blast crisis; TBI, total body irradiation; DLI, donor lymphocyte infusions | ||||||||||
| 14 | 44 | Fd/Bu ± ATG 11 AP | 26 CP 15 VUD 7 BC | 19 Sib | 52 | Cyto remission = 26/31 Mol remission = 19/31 | 14.8 | 15/44 | 41% at 18 mos | 24/44 |
| 15 | 17 | Fd/Bu/ATG Fd/Bu/TBI | 16 CP1 1 AP | 17 Sib | 35 | Mol remission = 5 | 30 | 8/17 | 5/17 | 6/17 |
| 16 | 24 | Fd/Bu/ATG | 24 CP1 5 VUD | 18 Sib 1 father | 35 | Mol remission = 100% (3 required DLI) | 42 | Day 100 = 0% 3 deaths | 85% at 5 yrs | 85% at 5 yrs |
| 17 | 12 | Fd + Cyclo (120 mg/kg) | 8 CP1 5 CP2 | 12 Sib | 43 | Cyto remission = 5 (6 mos) Mol remission = 4 (1 yr) 8 mol remission with additional therapy | 12 | Day 100 = 0% | 4 deaths from relapse | 8/12 |
| 18 | 15 | Fd/Bu/ATG | All CP1 | 10 Sib, 5 VUD | 51 | Mol remission = 11 | 20 | 2/15 | 9/15 | 13/15 |
| 19 | 35 | Cy 80–120 mg/kg/TBI (8 Gy) | 26 CP1 9 CP2/AP | 19 Sib, 16 VUD | 51 | Cyto remission = 100% Mol remission = 85% | 30 | Day 100 = 11% 1 year 28.5% | 49% at 5 yrs | 59% at 2 yrs |
| 20 | 186 | Various | 118 CP1 26 CP2 30 AP 12 BC | 113 Sib 20 Other related 52 VUD | 50 | Overall 86.9% | 35 | Day 100 = 3.8% 2 yr = 18.9% | 33% at 3 yrs CP 43% at 3 yrs | 54% at 3 yrs CP1 69% at 3 yrs |
| 21 | 24 | 2 Gy TBI ± Fd | 14 CP1 4 CP2 6 AP | 24 Sib | 57.5 | Cyto remission = 15 Mol remission = 13 | 36 | CP1 15% > CP1 12% | Relapse at 2 yrs CP1 22% >CP1 64% | CP1 70% > CP1 56% |
| 22 | 24 | Bu/Cy/Fd | 24 CP | 24 Sib | 41 | Mol remission = 18/24 | 15 | 8% | 20/24 at 27 mos | 92% at 27 mos |